Assessment
What checks out:
- There is a real €320 million funding programme for a national gene-therapy/RNA research initiative whose hub/coordinating centre is based at the University of Padova (Padua).
- The money comes from the EU's post-pandemic recovery fund — Italy's National Recovery and Resilience Plan (NRRP), financed by NextGenerationEU.
What does not check out — the central attribution:
- The claim that Ursula von der Leyen "approved" the grant is misleading. Reporting on the controversy states plainly that "the €320 million was not a cheque written by Ursula von der Leyen to a research centre… It formed part of Italy's National Recovery and Resilience Plan," and that "there is no evidence that Ursula von der Leyen personally directed the money to the project".
- Independent fact-checking of the viral version concludes the accusation "goes beyond the available evidence": the money "was not personally awarded by Ursula von der Leyen," and the project was selected and administered by Italy, not by the Commission President personally.
- The €320 million funded a nationwide network (dozens of universities, public research bodies and private partners), not a single Padua entity.
- On the underlying conflict-of-interest question, the EU transparency commissioner found no violation of EU conflict-of-interest rules regarding Heiko von der Leyen's role.
Reasoning:
- The claim mixes true elements (the €320M sum, the EU recovery-fund origin, the Padua-linked gene-therapy centre) with a false/misleading core — that von der Leyen personally approved the grant. Sources consistently describe this personal-approval framing as unsupported. The kernel of truth (EU/NRRP money reaching the centre) is real, but the claim as worded misattributes the decision, so it is largely misleading rather than accurate.
Overall validity: 30%